Role of cyclooxygenase-2 inhibitors in combination with radiation therapy in lung cancer

Clinical Lung Cancer

Volumn 4, Issue 6, 2003, Pages 356-365

  Liao, Zhongxing ^a   Komaki, Ritsuko ^a   Mason, Kathryn A ^a   Milas, Luka ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Celecoxib; Chemotherapy radiation therapy

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DAUNORUBICIN; DICLOFENAC; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; IBUPROFEN; INDOMETACIN; IRINOTECAN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PROSTAGLANDIN; PROSTAGLANDIN INHIBITOR; ROFECOXIB;

ANTINEOPLASTIC ACTIVITY; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM ULCER; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; ESOPHAGITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GENE OVEREXPRESSION; HEART INFARCTION; HUMAN; LUNG CANCER; MAXIMUM TOLERATED DOSE; NONHUMAN; PNEUMONIA; PRECANCER; PROSTAGLANDIN SYNTHESIS; RADIOSENSITIVITY; REVIEW; TREATMENT OUTCOME;

EID: 0038080148     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2003.n.015     Document Type: Article

References (114)

1. Cancer Facts&Figures 2001. Atlanta, GA: American Cancer Society; 2001.
2. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Nat Cancer Inst 1996; 88:1210-1215.
3. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17:2692-2699.
4. Curran W, Jr, Scott C, Langer C, et al. Phase III comparison of sequential vs. concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer (NSCLC): initial report of radiation therapy oncology group (RTOG) 9410. Proc Am Soc Clin Oncol 2000; 19:484a (Abstract #1891).
5. Salgia R, Skarin AT. Molecular abnormalities in lung cancer. J Clin Oncol 1998; 16:1207-1217.
6. Fong KM, Sekido Y, Minna JD. Molecular pathogenesis of lung cancer. J Thorac Cardiovasc Surg 1999; 118:1136-1152.
7. Fu JY, Masferrer JL, Seibert K, et al. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265:16737-16740.
8. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000; 37:431-502.
9. Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 1996; 270:G393-400.
10. O'Banion MK. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol 1999; 13:45-82.
11. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Part I). J Nat Cancer Inst Cancer Spectrum 1998; 90:1529-1536.
12. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Nat Cancer Inst Cancer Spectrum 1998; 90:1609-1620.
13. Eling TE, Curtis JF. Xenobiotic metabolism by prostaglandin H synthase. Pharmacol Ther 1992; 53:261-273.
14. Wiese FW, Thompson PA, Kadlubar FF. Carcinogen substrate specificity of human COX-1 and COX-2. Carcinogenesis 2001; 22:5-10.
15. Rioux, N, Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Clin Res 1998; 58:5354-5360.
16. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87:803-809.
17. Kawamori T, Rao CV, Seibert K, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58:409-412.
18. Jacoby RF, Seibert K, Cole CE, et al. The Cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res 2000; 60:5040-5044.
19. Oshima M, Murai N, Kargman S, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61:1733-1740.
20. Harris RE, Alshafie GA, Abou-Issa H, et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor, Cancer Res 2000; 60:2101-2103.
21. Fischer SM, Lo HH, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indumethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999; 25:231-240.
22. Grubbs CJ, Lubet RA, Koki AT, et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000; 60:5599-5602.
23. Shiotani H, Denda A, Yamamoto K, et al. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res 2001; 61:1451-1456.
24. Huang M, Stolina M, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998; 58:1208-1216.
25. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 58:4997-5001.
26. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58:3761-3764.
27. Watkins D, Lenzo J, Segal A, et al. Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer. Eur Repir J 1998; 14:412-418.
28. Bennett A, Berstock DA, Raja B, et al. Survival time after surgery is inversely related to the amounts of prostaglandins extracted from human breast cancers [proceedings]. Br J Pharmacol 1979; 66:451P.
29. Furuta Y, Hall ER, Sanduja S, et al. Prostaglandin production by murine tumors as a predictor for therapeutic response to indomethacin. Cancer Res 1988; 48:3002-3007.
30. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122:518-523.
31. Tang D, Honn KV. Eicosanoids and tumor cell metastasis. In: Harris JE, Braum DP, Anderson KM, eds. Prostaglandin Inhibitors in Tumor Immunology and Immunotherapy. Boca Raton, Fla: CRC Press; 1994:73-1108.
32. Koki A, Leahy KM, Masferrer JL. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Investig Drugs 1999; 1623-1638.
33. Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105:1589-1594.
34. Lin MT, Lee RC, Yang PC, et al. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Atk pathway. J Biol Chem 2001; 276:48997-49002.
35. Kozaki K, Koshikawa K, Tatematsu Y, et al. Multi-faceted analyses of a highly metastatic human lung cancer cell line NCI-H460-LNM35 suggest mimicry of inflammatory cells in metastasis. Oncogene 2001; 20:4228-4234.
36. Dohadwala M, Luo J, Zhu L, et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 2001; 276:20809-20812.
37. Kakiuchi Y, Tsuji S, Tsujii M, et al. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res 2002; 62:1567-1572.
38. Niki T, Kohno T, Iba S, et al. Frequent co-localization of Cox-2 and laminin-5 gamma 2 chain at the invasive front of early-stage lung adenocarcinomas. Am J Pathol 2002; 160:1129-1141.
39. Murata H, Kawamo S, Tsuji S, et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999; 94:451-455.
40. Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999; 282:1254-1257.
41. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999; 5:1001-1005.
42. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001; 7:861-867.
43. Brabender J, Park J, Metzger R, et al. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Anns Surg 2001; 235:440-443.
44. Duperron C, Castonguay A. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis 1997; 18:1001-1006.
45. Keith RL, Miller YE, Hoshikawa Y, et al. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res 2002; 62:734-740.
46. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Eng J Med 2000; 342:1946-1952.
47. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994; 5:138-146.
48. Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Sem Radit Oncol 2001; 11:290-299.
49. Fulton AM. Interactions of natural effector cells and prostaglandins in the control of metastasis. J Nat Cancer Inst 1987; 78:735-741.
50. Zaharski L, Costantini V, Moritz T, et al. Chronic nonsteroidal antiinflammatory drug use in a cohort of patients with advanced lung and colon cancer. In: Honn KV, Marnett LG, Nigam S, et al eds. Eicosanoids and Other Bioactive Lipids in Cancer and Radiation Injury. Boston, Mass: Kluwer Academic Publishers; 1991:497-501.
51. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60:1306-1311.
52. Watson AJ. Chemopreventive effects of NSAIDs against colorectal cancer: regulation of apoptosis and mitosis by COX-1 and COX-2. Histol Histopathol 1998; 13:591-597.
53. Smith ML, Hawcroft G, Hull MA. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Euro J Cancer 2000; 36:664-674.
54. Zhang Z, DuBois RN. Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. Gastroenterology 2000; 118:1012-1017.
55. Chan TA, Morin PJ, Vogelstein B, et al. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A 1998; 95:681-686.
56. Li M, Wu X, Xu XC. Induction of apoptosis by cyclo-oxygenase-2 inhibitor NS398 through a cytochrome C-dependent pathway in esophageal cancer cells. Int J Cancer 2001; 93:218-223.
57. Yamamoto Y, Yin M-J, Lin K-M, et al. Sulindac Inhibits Activation of the NF-kappa B Pathway. J Biol Chem 1999; 74:27307-27314.
58. Manson MM, Holloway KA, Howells LM, et al. Modulation of signal-transduction pathways by chemopreventive agents. Biochem Soc Trans 2000; 28:7-12.
59. Ziche M, Jones J, Gullino PM. Role of prostaglandin E1 and copper in angiogenesis. J Nat Cancer Inst 1982; 69:475-482.
60. Form DM, Auerbach R. PGE2 and angiogenesis. Proc Soc Exper Biol Med 1983; 172:214-218.
61. Milas L, Furuta Y, Hunter N, et al. Dependence of indomethacin-induced potentiation of murine tumor radioresponse oil tumor host immunocompetence. Cancer Res 1990; 50:4473-4477.
62. Furuta Y, Hunter N, Barkley T, Jr, et al. Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res 1988; 48:3008-3013.
63. Jones M, Wang H, Peskar B, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implication, for cancer growth and ulcer healing. Nat Med 1999; 5:1418-1423.
64. Masferrer J, Isakson P, Seibert K. Cyclooxygenase-2 inhibitors. A new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am 1996; 25:363-372.
65. Milas L, Kishi K, Hunter N, et al. Enhancement of tumor response to g-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 1999; 91:1501-1504.
66. Leung KH, Mihich E. Prostaglandin modulation of development of cell-mediated immunity in Culture. Nature 1980; 288:597-600.
67. Brunda M, Herberman R, Holden H. Inhibition of murine natural killer cell activity by prostaglandins. J Immunol 1980; 124:2682-2687.
68. Fulton AM, Levy, JG, The possible role of prostaglandins in mediating immune suppression by nonspecific T suppressor cells. Cell Immunol 1980; 52:29-37.
69. Kambayashi T, Alexander HR, Fong M, et al. Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol 1995; 154:3383-3390.
70. Castonguay A, Rioux N. Inhibition of lung tumorigenesis by sulindac: comparison of two experimental protocols. Carcinogenesis 1997; 18:491-496.
71. Huang M, Sharma S, Mao J, et al. Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol 1996; 157:5512-5520.
72. Stolina M, Sharma S, Lin Y, et al. Specific Inhibition of Cyclooxygenase 2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Synthesis. J Immunol 2000; 164:361-370.
73. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15 (12): 2057-2072.
74. Hanson WR. Eicosanoid-induced radioprotection and chemoprotection: Laboratory studies and clinical applicatons. In: Bump EA, Malaker K eds. Radioprotectors: Chemical, Biological and Clinical Perspectives. Boca Raton, Fla: CRC press; 1998: 197-221.
75. Milas L., Hanson W. Eicosanoids and radiation. Eur J Cancer 1995; 31A:1580-1585.
76. Hanson W, Thomas C. 16, 16-dimethyl prostaglandin E2 increases survival of murine intestinal stem cells when given before photon radiation. Radiat Res 1983; 96:393-398.
77. Hanson WR, Ainsworth EJ. 16,16-Dimethyl prostaglandin E2 induces radioprotection in murine intestinal and hematopoietic stem cells. Radiat Res 1985; 103:196-203.
78. Geng L, Hanson WR, Malkinson FD. Topical or systemic 16, 16 dm prostaglandin E2 or WR-2721 (WR-1065) protects mice from alopecia after fractionated irradiation. Int J Radiat Biol 1992; 61:533-537.
79. van Buul PP, van Duyn-Goedhart A, de Rooij DG, et al. Differential radioprotective effects of misoprostol in DNA repair-proficient and -deficient or radiosensitive cell systems. Int J Radiat Biol 1997; 71:259-264.
80. van Buul PP, van Duyn-Goedhart A, Sankaranarayanan K. In vivo and in vitro radioprotective effects of the prostaglandin E1 analogue misoprostol in DNA repair-proficient and -deficient rodent cell systems. Radiat Res 1999; 152:398-403.
81. Zaffaroni N, Villa R, Orlandi L, et al. Differential effect of 9 beta-chloro-16, 16-dimethyl prostaglandin E2 (nocloprost) on the radiation response of human normal fibroblasts and colon adenocarcinoma cells. Radiat Res 1993; 135:88-92.
82. Hanson W, Geng L, Malkinson F. Prostaglandin-induced protection from radiation or doxorubicin is tissue specific and dependent upon receptor expression. Tenth International Congress of Radiation Research, Wurzburg, Germany 1995:435.
83. Houchen CW, Stenson WF, Cohn SM. Disruption of cyclooxygenase-1 gene results in an impaired response to radiation injury. Am J Physiol Gastrointest Liver Physiol 2000; 279:G858-865.
84. Teichei BA, Bump EA, Palayoor ST, et al. Signal transduction inhibitors as modifiers of radiation therapy in human prostate carcinoma xenografts. Radiat Oncol Invest 1996; 221-230.
85. Kishi K, Petersen S, Petersen C, et al. Preferential enhancement of tumor radioresponse by a cyclooxgenase-2 inhibitor. Cancer Res 2000; 60:1326-1331.
86. Petersen C, Petersen S, Milas L, et al. Human Glioma Cell Radiosensitization by a Selective COX-2 Inhibitor. Clin Cancer Res 2000; 6:2513-2520.
87. Pyo H, Choy H, Amorino GP, et al. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 2001; 7:2998-3005.
88. Davis T, Hunter N, Trifan OC, et al. COX-2 Inhibitors as radiosensitizing agents for cancer therapy. Am J Clin Oncol 2003. In press.
89. Milas L, Mason K, Liao Z, et al. Role of cyclooxygenase-2 (COX-2) and its inhibition in tumor biology and radiotherapy. In: Nieder C, Milas L, Ang KK eds. Modification of radiation response, cytokines, growth factors, and other biological targets. New York: Springer-Verlag Berlin Heidelberg 2003:240-258.
90. Raju U, Nakata E, Yang P, et al. In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. Int J Radiat Oncol Biol Phys 2002; 54:886-894.
91. Mijima M, Hayashi I, Muramatsu M, et al. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 2000; 130:641-649.
92. Rak J, Filmus J, Kerbel RS. Reciprocal paracrine interactions between tumour cells and endotheial cells: the 'angiogenesis progression' hypothesis. Eur J Cancer 1996; 32A:2438-2450.
93. Dicker AR, Williams TL, Grant DS. Targeting angiogenic processes by combination refecoxib and ionizing radiation. J Clin Oncol 2001; 24:438-442.
94. Teicher BA, Holden SA, Dupuis NP, et al. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice hearing EMT-6 mammary carcinoma. Breast Cancer Res Treat 1995; 36:227-236.
95. Gorski DH, Beckett MA, Jaskowiak NT et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999; 59:3374-3378.
96. Gorski DH, Mauceri HJ, Salloum RM, et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 1998; 58:5686-5689.
97. Milas L, Hunter NR, Mason KA, et al. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 1995; 55:3564-3568.
98. Mason KA, Kishi K, Hunter N, et al. Effect of docetaxel oil the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res 1999; 5:4191-4198.
99. Li L, Rojiani A, Siemann DW. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects oil radiation therapy. Int J Radiat Oncol Biol Phys 1998; 42:335-363.
100. Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000; 6:701-708.
101. Haimovitz-Friedman A, Vlodavsky I, Chaudhuri A, et al. Autocrine effects of fibroblast growth factor in repair of radiation damage in endothelial cells. Cancer Res 1991; 51:2552-2558.
102. Steinauer KK, Gibbs I, Ning S, et al. Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. Int J Radiat Oncol Biol Phys 2000; 48:325-328.
103. Torrance CJ, Jackson PE, Montgomery E, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000; 6:1024-1028.
104. Harari PM, Huang SM. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Sem Radiat Oncol 2001; 11:281-290.
105. Hida T, Kozaki K, Muramatsu H, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000; 6:2006-2011.
106. Duffy C, Elliott C, O'Connor R, et al. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 1998; 34:1250-1259.
107. Trifan OC, Durham WF, Salazar VS, et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 2002; 62:5778-5784.
108. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255.
109. Cleland LG, James MJ, Stamp LK, et al. COX-2 inhibition and thrombotic tendency: a need for surveillance. Med J Aust 2001; 175:214-217.
110. Mukherjee D, Nissen SE, Topol EJ, et al. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286:954-959.
111. Howes LG, Krum H. Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link? Drug Saf 2002; 25:829-835.
112. Carbone D, Choy H, Csiki I, et al. Serum/plasma VEGF level changes with cyclooxygenase-2 (COX-2) inhibition in combined modality therapy in stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II trial (THO-0059). Proc Am Soc Clin Oncol 2002; 21:318a (Abstract #270).
113. Csiki I, Dang T, Gonzalez A, et al. Cyclooxygenase-2 (COX-2) inhibition + docetaxel (Txt) in recurrent non-small cell lung cancer (NSCLC): preliminary results of a phase II trail (THO-0054). Proc Am Soc Cli Oncol 2002; 21:297a (Abstract #1187).
114. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib (Celebrex), a selective COX-2 inhibitor, enhances the response to preoperative paclitaxel/carboplatin in early stage non-small cell lung cancer. Proc Am Soc Clin Oncol 2002:26a (Abstract #101).